Creative Biolabs Launches Antibody Tools for Neuroscience and Muscle Genetics Research
TL;DR
Creative Biolabs' new antibody products for GRID2, TH, and ACTN3 research give scientists a competitive edge in developing targeted neurological treatments and muscle disorder therapies.
Creative Biolabs provides specific antibodies that enable researchers to systematically study synaptic proteins, neurotransmitter synthesis, and muscle genetics through established methods like Western blot and immunohistochemistry.
These research tools advance understanding of neurological diseases and muscle disorders, potentially leading to better treatments that improve quality of life for patients worldwide.
Discover how Creative Biolabs' antibody products help researchers map synaptic function and muscle genetics, revealing fascinating connections between molecular biology and human movement.
Found this article helpful?
Share it with your network and spread the knowledge!
Creative Biolabs has introduced a comprehensive suite of antibody tools designed to advance research in neuroscience and muscle genetics, targeting critical markers including GRID2, tyrosine hydroxylase, and ACTN3. These specialized reagents address the growing global burden of neurodegenerative diseases, movement disorders, and psychiatric conditions by enabling more precise investigation of molecular mechanisms underlying these conditions.
The GRID2 gene has emerged as a significant focus in neurological research, with studies demonstrating that mutations in this gene can lead to cerebellar ataxia and learning deficits. GRID2 plays a dominant role in motor coordination and synaptic transmission, making it a valuable target for understanding neural circuit imbalances. Creative Biolabs has developed anti-GRID2 antibody products including Rabbit Anti-GRID2 Recombinant Antibody and Mouse Anti-GRID2 Recombinant Antibody, which are applicable in ELISA, flow cytometry, Western blotting, and immunohistochemistry applications. These highly specific tools allow researchers to accurately study spatial characteristics and dynamic regulation of synaptic proteins, potentially accelerating discoveries in cerebellar development and mechanism learning.
In neurotransmitter metabolism research, tyrosine hydroxylase (TH) represents another critical target as the rate-limiting enzyme in catecholamine synthesis. TH catalyzes the conversion of L-tyrosine to L-DOPA, which subsequently produces dopamine, norepinephrine, and epinephrine. This enzyme serves as an important marker for drug discovery and disease diagnosis, particularly in Parkinson's disease research where changes in TH levels reflect the functional state of dopaminergic neurons. Creative Biolabs offers the Mouse Anti-Tyrosine Hydroxylase Recombinant Antibody (AV1), optimized for Western blot and immunohistochemistry applications, enabling sensitive detection of molecular changes along neurotransmitter synthesis pathways.
Beyond neuroscience applications, the company has expanded into muscle genetics with ACTN3-targeted products. The ACTN3 gene encodes α-actinin-3, a critical protein for maintaining structural integrity and explosive power in fast-twitch muscle fibers. Creative Biolabs provides ACTN3-related products including Mouse Anti-ACTN3 Recombinant Antibody for IHC and WB applications, and Rabbit Anti-ACTN3 Recombinant Antibody for WB, IH, IC, and Flow applications. These tools support research in sports genetics, muscle disorders, and personalized training, offering high specificity and cross-species applications that could advance understanding of genetic factors influencing athletic performance and muscle-related diseases.
The development of these specialized antibody tools represents a significant advancement for researchers investigating complex neurological and muscular systems. By providing highly specific reagents for key molecular targets, Creative Biolabs enables more precise mapping of molecular pathways in cell and animal model systems. This capability could accelerate the discovery of new treatment approaches for conditions ranging from Parkinson's disease and cerebellar ataxia to muscle disorders and genetic athletic performance factors. The availability of these research tools may contribute to faster translation of basic research findings into clinical applications, potentially impacting drug development timelines and therapeutic strategies for millions affected by neurological and muscular conditions worldwide.
Curated from 24-7 Press Release
